Commitments and Contingencies (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2012
Abraxis Bio Science, Inc.
Product Liability Contingency [Line Items]
Intangible asset				$ 1,172,000,000
ABRAXANE
Product Liability Contingency [Line Items]
Nonfinancial liabilities		$ 51,900,000	$ 136,300,000
CVR milestone payment		$ 250,000,000.0
Net sales measurement period		1 year
Milestone payment made	$ 300,000,000
ABRAXANE | If Achieved no later than April 1, 2013
Product Liability Contingency [Line Items]
CVR milestone payment		$ 400,000,000.0
ABRAXANE | If Achieved after April 1, 2013 and before the fifth anniversary of the Merger
Product Liability Contingency [Line Items]
CVR milestone payment		$ 300,000,000.0
ABRAXANE | Milestone One
Product Liability Contingency [Line Items]
Royalty rate		2.50%
ABRAXANE | Milestone One | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		$ 1,000,000,000.000
ABRAXANE | Milestone One | Maximum
Product Liability Contingency [Line Items]
Revenue milestones		$ 2,000,000,000.000
ABRAXANE | Milestone Two
Product Liability Contingency [Line Items]
Royalty rate		5.00%
ABRAXANE | Milestone Two | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		$ 2,000,000,000.000
ABRAXANE | Milestone Two | Maximum
Product Liability Contingency [Line Items]
Revenue milestones		$ 3,000,000,000.000
ABRAXANE | Milestone Three
Product Liability Contingency [Line Items]
Royalty rate		10.00%
ABRAXANE | Milestone Three | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		$ 3,000,000,000.000
ABRAXANE | Termination date of December 31, 2025 if sales less than $1.0 billion | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		1,000,000,000.000
ABRAXANE | Termination date of December 31, 2030 or earlier if sales less than $1.0 billion | Minimum
Product Liability Contingency [Line Items]
Revenue milestones		$ 1,000,000,000.000